These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 22763628)

  • 1. Circulating free testosterone is an independent predictor of advanced disease in patients with clinically localized prostate cancer.
    Schnoeller T; Jentzmik F; Rinnab L; Cronauer MV; Damjanoski I; Zengerling F; Ghazal AA; Schrader M; Schrader AJ
    World J Urol; 2013 Apr; 31(2):253-9. PubMed ID: 22763628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sex hormone-binding globulin is a significant predictor of extracapsular extension in men undergoing radical prostatectomy.
    Salonia A; Gallina A; Briganti A; Zanni G; Suardi N; Capitanio U; Colombo R; Bertini R; Freschi M; Guazzoni G; Rigatti P; Montorsi F
    BJU Int; 2011 Apr; 107(8):1243-9. PubMed ID: 20883480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative sex steroids are significant predictors of early biochemical recurrence after radical prostatectomy.
    Salonia A; Abdollah F; Capitanio U; Gallina A; Suardi N; Briganti A; Zanni G; Ferrari M; Castiglione F; Clementi MC; Rigatti P; Montorsi F
    World J Urol; 2013 Apr; 31(2):275-80. PubMed ID: 22441310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative circulating sex hormones are not predictors of positive surgical margins at open radical prostatectomy.
    Salonia A; Gallina A; Abdollah F; Briganti A; Capitanio U; Suardi N; Ferrari M; Raber M; Colombo R; Freschi M; Rigatti P; Montorsi F
    World J Urol; 2012 Aug; 30(4):533-9. PubMed ID: 21935733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating estradiol, but not testosterone, is a significant predictor of high-grade prostate cancer in patients undergoing radical prostatectomy.
    Salonia A; Gallina A; Briganti A; Suardi N; Capitanio U; Abdollah F; Bertini R; Freschi M; Rigatti P; Montorsi F
    Cancer; 2011 Nov; 117(22):5029-38. PubMed ID: 21495024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The preoperative serum ratio of total prostate specific antigen (PSA) to free testosterone (FT), PSA/FT index ratio, and prostate cancer. Results in 220 patients undergoing radical prostatectomy.
    Porcaro AB; Caruso B; Terrin A; De Luyk N; Cacciamani G; Corsi P; Inverardi D; De Marchi D; Baldassarre R; Cerruto M; Ghimenton C; Brunelli M; Zecchini Antoniolli S; Petrozziello A; Artibani W
    Arch Ital Urol Androl; 2016 Mar; 88(1):17-22. PubMed ID: 27072171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigative clinical study on prostate cancer part IX and X: estradiol and the pituitary-testicular-prostate axis at the time of initial diagnosis and subsequent cluster selection of the patient population after radical prostatectomy.
    Porcaro AB; Ghimenton C; Petrozziello A; Sava T; Migliorini F; Romano M; Caruso B; Cocco C; Antoniolli SZ; Lacola V; Rubilotta E; Monaco C
    Anticancer Res; 2012 Oct; 32(10):4523-32. PubMed ID: 23060581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum sex steroids depict a nonlinear u-shaped association with high-risk prostate cancer at radical prostatectomy.
    Salonia A; Abdollah F; Capitanio U; Suardi N; Briganti A; Gallina A; Colombo R; Ferrari M; Castagna G; Rigatti P; Montorsi F
    Clin Cancer Res; 2012 Jul; 18(13):3648-57. PubMed ID: 22589393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations of pretreatment serum total testosterone measurements with pathology-detected Gleason score cancer.
    Porcaro AB; Petrozziello A; Ghimenton C; Migliorini F; Sava T; Caruso B; Romano M; Cavalleri S; Artibani W
    Urol Int; 2014; 93(3):269-78. PubMed ID: 24334919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study of testosterone as a predictor of tumor aggressiveness in patients with prostate cancer.
    Cabral PH; Iwamoto MW; Fanni VS; Barros Lda R; Cardoso SN; Mello LF; Glina S
    Int Braz J Urol; 2013; 39(2):173-81. PubMed ID: 23683664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Follicle-stimulating hormone and the pituitary-testicular-prostate axis at the time of initial diagnosis of prostate cancer and subsequent cluster selection of the patient population undergoing standard radical prostatectomy.
    Porcaro AB; Migliorini F; Petrozziello A; Sava T; Romano M; Caruso B; Cocco C; Ghimenton C; Zecchinini Antoniolli S; Lacola V; Rubilotta E; Monaco C; Comunale L
    Urol Int; 2013; 90(1):45-55. PubMed ID: 23128438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low circulating free and bioavailable testosterone levels as predictors of high-grade tumors in patients undergoing radical prostatectomy for localized prostate cancer.
    Léon P; Seisen T; Cussenot O; Drouin SJ; Cattarino S; Compérat E; Renard-Penna R; Mozer P; Bitker MO; Rouprêt M
    Urol Oncol; 2015 Sep; 33(9):384.e21-7. PubMed ID: 25595576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Corpulence is the crucial factor: association of testosterone and/or obesity with prostate cancer stage.
    Jentzmik F; Schnoeller TJ; Cronauer MV; Steinestel J; Steffens S; Zengerling F; Al Ghazal A; Schrader MG; Steinestel K; Schrader AJ
    Int J Urol; 2014 Oct; 21(10):980-6. PubMed ID: 24865433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dihydrotestosterone and testosterone levels in men screened for prostate cancer: a study of a randomized population.
    Gustafsson O; Norming U; Gustafsson S; Eneroth P; Aström G; Nyman CR
    Br J Urol; 1996 Mar; 77(3):433-40. PubMed ID: 8814852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative serum sex hormone-binding globulin as a predictive marker for extraprostatic extension of tumor in patients with clinically localized prostate cancer.
    Lee SE; Chung JS; Han BK; Park CS; Moon KH; Byun SS; Choe G; Hong SK
    Eur Urol; 2008 Dec; 54(6):1324-32. PubMed ID: 18339472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative hormonal pattern in patients undergoing radical prostatectomy due to prostate cancer.
    García-Cruz E; Castañeda-Argáiz R; Carrión A; Alcover J; Sallent A; Leibar-Tamayo A; Romero-Otero J; Alcaraz A;
    Actas Urol Esp; 2013 May; 37(5):280-5. PubMed ID: 23246101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum testosterone improves the accuracy of Prostate Health Index for the detection of prostate cancer.
    Friedersdorff F; Manus P; Miller K; Lein M; Jung K; Stephan C
    Clin Biochem; 2014 Jul; 47(10-11):916-20. PubMed ID: 24530341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The correlation between serum prostate-specific antigen and prostate cancer is not influenced by the serum testosterone concentration.
    Monda JM; Myers RP; Bostwick DG; Oesterling JE
    Urology; 1995 Jul; 46(1):62-4. PubMed ID: 7541588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients.
    Douglas TH; Morgan TO; McLeod DG; Moul JW; Murphy GP; Barren R; Sesterhenn IA; Mostofi FK
    Cancer; 1997 Jul; 80(1):107-14. PubMed ID: 9210715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-Müllerian hormone: a novel biomarker for aggressive prostate cancer? Emerging evidence from a prospective study of radical prostatectomies.
    Kontogiannis S; Markantes G; Stamou M; Tsagkarakis M; Mamali I; Giannitsas K; Perimenis P; Georgopoulos N; Athanasopoulos A
    Hormones (Athens); 2024 Jun; 23(2):297-304. PubMed ID: 38127275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.